To schedule a new patient appointment call 844-CANCERNJ (844-226-2376)
To schedule a follow-up appointment call 732-235-7615
For all other inquiries call 732-235-2465.
I am a hematologist with a focus on blood cancers and stem cell transplantation, and I’ve been fortunate to work in this field for over 30 years. I completed my medical degree at the Institute of Medical Sciences in Varanasi, India, before moving to the United States for residency training in Internal Medicine at Long Island Jewish Medical Center in New York. I then completed a fellowship in Hematology and Oncology at the MD Anderson Cancer Center in Houston, Texas, where I focused extensively on hematologic malignancies and stem cell transplant.
Throughout my career, I’ve helped build and expand stem cell transplant programs at several leading institutions, including the University of Massachusetts Medical Center and Banner MD Anderson Cancer Center. Today, I serve as the Director of Research in Blood and Marrow Transplantation at the Rutgers Cancer Institute of New Jersey, an NCI-designated cancer center.
Whether I’m working with patients or collaborating with colleagues, my guiding philosophy is the same: I am aggressive toward the disease but conservative toward the patient. I believe that medicine is both a science and a relationship. I take the time to understand each patient’s goals, values, and risk tolerance, and I develop personalized treatment plans that reflect those priorities. I also work closely with an interdisciplinary team to ensure that care is not only evidence-based but also compassionate and comprehensive.
Outside of work, I enjoy traveling and spending time with my wife, Anupma, and our two children, Pranay and Hetal, who are both currently in college.
Cord blood stem cell transplantation, stem cell transplant in older adults, transplantation in high-risk patients, including those with significant comorbidities or advanced disease, development of novel conditioning regimens and GVHD prophylaxis strategies in allogeneic stem cell transplantation, and expanding access to transplant and improving outcomes through personalized and innovative treatment approaches.
Munoz J, Flinn IW, Cohen JB, Sachs J, Exter B, Ranger A, Harris P, Payumo F, Nath R, Hamadani M, Westin JR. Results from a phase 1 study of ACTR707 in combination with rituximab in patients with relapsed or refractory CD20+ B cell lymphoma. Transplantation and Cellular Therapy. 2024 Feb 1;30(2):241-e1.
Ferrarotto R, Swiecicki PL, Zandberg DP, Baiocchi RA, Wesolowski R, Rodriguez CP, McKean M, Kang H, Monga V, Nath R, Palmisiano N. PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: an open-label, phase I dose-expansion study. Oral oncology. 2024 Feb 1; 149:106634.
Cammann E, Madhav S, Hutchinson L, Cerny J, Ramanathan M, Bledsoe JR, Makarenko V, Patel SA, Meng X, Tomaszewicz K, Nath R, Chen B, Woda B, Selove W. Frameshift Mutations in Leukemia-Associated Genes Correlate with Superior Outcomes in Patients Undergoing Allogeneic Stem Cell Transplant for De Novo Acute Myeloid Leukemia. Journal of Hematology. 2024 Jun 28;13(3):86-93.
Gyurkocza B, Nath R, Seropian S, Choe H, Litzow MR, Abboud C, Koshy N, Stiff P, Tomlinson B, Abhyankar S, Foran J. Randomized phase III SIERRA Trial of 131I-Apamistamab before allogeneic hematopoietic cell transplantation versus conventional Care for Relapsed/refractory AML. Journal of Clinical Oncology. 2025 Jan 10;43(2):201-13.
Locke FL, Munoz JL, Tees MT, Lekakis LJ, de Vos S, Nath R, Stevens DA, Malik SA, Shouse GP, Hamadani M, Oluwole OO. Allogeneic chimeric antigen receptor T-cell products cemacabtagene ansegedleucel/ALLO-501 in relapsed/refractory large B-cell lymphoma: Phase I experience from the ALPHA2/ALPHA clinical studies. Journal of Clinical Oncology. 2025 May 10;43(14):1695-705.
Furqan F, Ahn KW, Kaur M, Patel J, Ansell S, Awan FT, Baird J, Bezerra E, Farooq U,Fung H, Khurana A, Lekakis L, Lutfi F, McCarty J, Mukherjee A, Nath R, Romancik J, Schuster SJ , Smith M, Winter A, Turtle C, Sauter C, Shadman M, Herrara A, HamadanI M. Autologous Transplant or CAR-T as Consolidation Options in MYC Rearranged Large B-Cell Lymphoma Patients in Remission After Salvage Treatments. American Journal of Hematology. 2025; 100:1152–1162.
Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, Godwin JE, Reagan PM, Wagner-Johnston ND, Essell J, Nath R, Solomon S, Champion R, Licitra E, Fanning S, Gupta NK, Chow VA, Yuan B, Yang Z, Ogasawara K, Thorpe J,Gordon LI. Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study. Blood Advances. 2025 Aug 12;9(15):3694-705.
Accepted Health Plan information is only as accurate as the most current information submitted. Prior to your appointment, it is advisable to verify with your insurance company they are still a participating plan prior to receiving services or care. Each plan is different and some provide different levels of coverage that could make a difference in your out-of-pocket costs. It is always best for the patient receiving care to contact their insurance company to obtain more information.